M Belhassen1,2,3, C B Confavreux4, B Cortet5, L Lamezec6, M Ginoux7,8, E Van Ganse7,8,9. 1. Merck Sharp and Dohme, Paris, France. Manon.belhassen@univ-lyon1.fr. 2. PELyon, PharmacoEpidemiologie Lyon, Faculté d'Odontologie, 11 rue Guillaume Paradin, F-69372, Lyon, Cedex 08, France. Manon.belhassen@univ-lyon1.fr. 3. HESPER 7425, Health Services and Performance Research, Claude Bernard Lyon 1 University, Lyon, France. Manon.belhassen@univ-lyon1.fr. 4. INSERM UMR 1033-University of Lyon, Rheumatology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. 5. Department of Rheumatology and EA 4490, Lille University Hospital, Lille, France. 6. Merck Sharp and Dohme, Paris, France. 7. PELyon, PharmacoEpidemiologie Lyon, Faculté d'Odontologie, 11 rue Guillaume Paradin, F-69372, Lyon, Cedex 08, France. 8. HESPER 7425, Health Services and Performance Research, Claude Bernard Lyon 1 University, Lyon, France. 9. Respiratory Medicine, Croix-Rousse University Hospital, Lyon, France.
Abstract
Limited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006-2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistence with anti-osteoporotic treatment was low, with high proportions of treatment discontinuations and switches. INTRODUCTION: This epidemiological, longitudinal study described first-line treatment initiation, persistence, switches to second-line treatment, and medical care consumption in osteoporotic patients in France during the 2007-2013 period. METHODS: Patients aged ≥50 years, who were recorded in a French claims database and did not die during the observation period, were included if they met ≥1 inclusion criteria for osteoporosis in 2007 (≥1 reimbursement for anti-osteoporotic treatment, hospitalisation for osteoporotic fracture (spine, hip, femur, forearm bones, humerus, wrist), or ≥1 reimbursement for long-term osteoporosis-associated status). We collected data on consumption of anti-osteoporotic treatment (alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, raloxifene, strontium ranelate, teriparatide) and of osteoporosis-related medical care after the date of first reimbursement for anti-osteoporotic treatment. RESULTS: We obtained 2219 patients with a 6-year follow-up and 1387 who initiated an anti-osteoporotic treatment in 2007 and who can be selected for the treatment regimen analysis. The most frequently used first-line treatments were alendronic acid (32.7 %), risedronic acid (22.4 %), strontium ranelate (19.3 %), ibandronic acid (13.1 %) and raloxifene (12.2 %). Among patients who received these treatments, the highest persistence after 6 years was observed for raloxifene (37.3 %), alendronic acid (35.1 %) and risedronic acid (32.3 %). Treatment discontinuations were reported for 35.5 % (raloxifene) to 53.4 % (strontium ranelate) and treatment switches for 27.4 % (alendronic acid) to 56.6 % (ibandronic acid) of these patients. CONCLUSIONS: This study showed that persistence with anti-osteoporotic treatment was relatively low in France, with high proportions of treatment discontinuations and switches, and that patients with osteoporosis were insufficiently monitored by bone specialists.
Limited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006-2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistence with anti-osteoporotic treatment was low, with high proportions of treatment discontinuations and switches. INTRODUCTION: This epidemiological, longitudinal study described first-line treatment initiation, persistence, switches to second-line treatment, and medical care consumption in osteoporoticpatients in France during the 2007-2013 period. METHODS:Patients aged ≥50 years, who were recorded in a French claims database and did not die during the observation period, were included if they met ≥1 inclusion criteria for osteoporosis in 2007 (≥1 reimbursement for anti-osteoporotic treatment, hospitalisation for osteoporotic fracture (spine, hip, femur, forearm bones, humerus, wrist), or ≥1 reimbursement for long-term osteoporosis-associated status). We collected data on consumption of anti-osteoporotic treatment (alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, raloxifene, strontium ranelate, teriparatide) and of osteoporosis-related medical care after the date of first reimbursement for anti-osteoporotic treatment. RESULTS: We obtained 2219 patients with a 6-year follow-up and 1387 who initiated an anti-osteoporotic treatment in 2007 and who can be selected for the treatment regimen analysis. The most frequently used first-line treatments were alendronic acid (32.7 %), risedronic acid (22.4 %), strontium ranelate (19.3 %), ibandronic acid (13.1 %) and raloxifene (12.2 %). Among patients who received these treatments, the highest persistence after 6 years was observed for raloxifene (37.3 %), alendronic acid (35.1 %) and risedronic acid (32.3 %). Treatment discontinuations were reported for 35.5 % (raloxifene) to 53.4 % (strontium ranelate) and treatment switches for 27.4 % (alendronic acid) to 56.6 % (ibandronic acid) of these patients. CONCLUSIONS: This study showed that persistence with anti-osteoporotic treatment was relatively low in France, with high proportions of treatment discontinuations and switches, and that patients with osteoporosis were insufficiently monitored by bone specialists.
Entities:
Keywords:
First-line treatment; France; Medical care; Osteoporosis; Persistence; Switch
Authors: François-Emery Cotté; Bernard Cortet; Antoine Lafuma; Bernard Avouac; Abdelkader El Hasnaoui; Patrice Fardellone; Denis Pouchain; Christian Roux; Anne-Françoise Gaudin Journal: Joint Bone Spine Date: 2007-08-31 Impact factor: 4.929
Authors: Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki Journal: Am J Med Date: 2012-11-20 Impact factor: 4.965
Authors: J Pepe; C Cipriani; V Cecchetti; C Ferrara; G Della Grotta; V Danese; L Colangelo; S Minisola Journal: Osteoporos Int Date: 2019-05-14 Impact factor: 4.507
Authors: Olga Růžičková; Zdenko Killinger; Petr Kasalický; Lisa Hamilton; Roman Tyl; Soňa Tomková; Lama Kalouche-Khalil Journal: Adv Ther Date: 2018-09-06 Impact factor: 3.845